Citi analyst Samantha Semenkow has maintained their bullish stance on EDIT stock, giving a Buy rating yesterday.
Samantha Semenkow’s rating is based on Editas Medicine’s promising advancements in their in vivo HSC and liver programs, which are on track for development candidate selection by mid-2025. The company has shown encouraging preclinical data, particularly in their sickle cell disease program, where significant allelic editing has been achieved in non-human primates and mice. This progress suggests potential curative outcomes, as management believes a minimum of 20% allelic editing is necessary for curative intent in humans.
Additionally, Editas Medicine’s liver program has demonstrated substantial preclinical proof-of-concept, with impressive liver editing results and biomarker reductions in non-human primates. The company’s financial position is strong, with sufficient cash to fund operations into the second quarter of 2027, allowing them to reach clinical proof-of-concept in at least one indication by the end of 2026. These factors contribute to the Buy rating, reflecting the high potential for significant share price appreciation.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $5.00 price target.
EDIT’s price has also changed dramatically for the past six months – from $3.590 to $1.780, which is a -50.42% drop .